Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis.
CK-18
Elastography
FIB-4
HCV
Liver fibrosis
sST2
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
05
06
2023
accepted:
29
12
2023
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
30
1
2024
Statut:
epublish
Résumé
With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C. 424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman's correlation and AUROC analyses. Data of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman's rho = 0.39 and rho = 0.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65-0.83), and 0.67(95%CI 0.56-0.78) for the discrimination of F3/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests. sST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C.
METHODS
METHODS
424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman's correlation and AUROC analyses.
RESULTS
RESULTS
Data of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman's rho = 0.39 and rho = 0.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65-0.83), and 0.67(95%CI 0.56-0.78) for the discrimination of F3/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests.
CONCLUSIONS
CONCLUSIONS
sST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.
Identifiants
pubmed: 38291388
doi: 10.1186/s12876-023-03116-4
pii: 10.1186/s12876-023-03116-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : Universität Zürich
ID : Walter and Gertrud Siegenthaler Fellowship
Organisme : Novartis Foundation
ID : 23A064
Informations de copyright
© 2024. The Author(s).
Références
Jiang S-W, Wang P, Xiang X-G, Mo R-D, Lin L-Y, Bao S-S, Lu J, Xie Q. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatob & Pancreat Diseases Int. 2017;16(2):181–8.
doi: 10.1016/S1499-3872(16)60185-6
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.
pubmed: 16298014
doi: 10.1016/j.jhep.2005.10.013
Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, et al. Disease Progression in patients with Hepatitis C virus infection treated with Direct-Acting Antiviral agents. Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterol Association. 2020;18(11):2554–2563e2553.
doi: 10.1016/j.cgh.2020.02.044
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H et al. Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. Clin Infect Dis 2021.
Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M. EASL Clinical Practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis– 2021 update. J Hepatol. 2021;75(3):659–89.
doi: 10.1016/j.jhep.2021.05.025
EASL recommendations on treatment of hepatitis C. Final update of the series(☆). J Hepatol. 2020;73(5):1170–218.
Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus infection. Hepatology. 2020;71(2):686–721.
pubmed: 31816111
doi: 10.1002/hep.31060
Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterol Association. 2015;13(4):772–9. e771-773.
Friedrich-Rust M, Ong M, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient Elastography for the staging of liver fibrosis: a Meta-analysis. Gastroenterology. 2008;134(4):960–974e968.
pubmed: 18395077
doi: 10.1053/j.gastro.2008.01.034
Ganne-Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet J-C, Beaugrand M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44(6):1511–7.
pubmed: 17133503
doi: 10.1002/hep.21420
Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet J-C, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48–54.
pubmed: 15690481
doi: 10.1002/hep.20506
Lu M, Li J, Zhang T, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Xu F, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 2016;14(7):1044–1055e1043.
pubmed: 26804385
pmcid: 5726250
doi: 10.1016/j.cgh.2016.01.009
Bachofner JA, Valli PV, Kroger A, Bergamin I, Kunzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37(3):369–76.
pubmed: 27678216
doi: 10.1111/liv.13256
He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic Value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Biomed Res Int. 2017;2017:9729107.
Huan SL, Zhao JG, Wang ZL, Gao S, Wang K. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. BMC Infect Dis. 2016;16:200.
pubmed: 27180842
pmcid: 4868038
doi: 10.1186/s12879-016-1543-x
Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284(5):1104–8.
pubmed: 11414697
doi: 10.1006/bbrc.2001.5090
Oztas E, Kuzu UB, Zengin NI, Kalkan IH, Saygili F, Yildiz H, Celik HT, Akdogan M, Kilic MY, Koksal AS et al. Can serum ST2 levels be used as a marker of Fibrosis in Chronic Hepatitis B infection? 2015;94(47):e1889.
Shalby MM, Ibrahim SA, Behairy OG, Behiry EG, Mahmoud DA. Diagnostic value of serum cytokeratin-18 in children with chronic liver disease. J Paediatr Child Health. 2020;56(1):41–6.
pubmed: 31054236
doi: 10.1111/jpc.14488
Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for assessing liver fibrosis in Chronic Liver diseases. Annals of Laboratory Medicine. 2018;38(4):331–7.
pubmed: 29611383
pmcid: 5895862
doi: 10.3343/alm.2018.38.4.331
Tan Z, Liu Q, Jiang R, Lv L, Shoto SS, Maillet I, Quesniaux V, Tang J, Zhang W, Sun B, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol. 2018;15(4):388–98.
pubmed: 28194023
doi: 10.1038/cmi.2016.63
Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Front Immunol. 2018;9:2432.
pubmed: 30405626
pmcid: 6207585
doi: 10.3389/fimmu.2018.02432
Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124(4):1206–14.
pubmed: 14555548
doi: 10.1378/chest.124.4.1206
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–6.
pubmed: 12578875
doi: 10.1161/01.CIR.0000047274.66749.FE
Marvie P, Lisbonne M, L’Helgoualc’h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Théret N, Gascan H, Piquet-Pellorce C, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. 2010;14(6b):1726–39.
pubmed: 19508382
doi: 10.1111/j.1582-4934.2009.00801.x
Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285(5):1377–83.
pubmed: 11478810
doi: 10.1006/bbrc.2001.5306
Wang J, Zhao P, Guo H, Sun X, Jiang Z, Xu L, Feng J, Niu J, Jiang Y. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C. Mediators Inflamm. 2012;2012:819636.
pubmed: 22315510
pmcid: 3270460
doi: 10.1155/2012/819636
Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, Zeuzem S. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat. 2005;12(3):307–14.
pubmed: 15850472
doi: 10.1111/j.1365-2893.2005.00594.x
Rau M, Schilling A-K, Meertens J, Hering I, Weiss J, Jurowich C, Kudlich T, Hermanns HM, Bantel H, Beyersdorf N, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the liver. J Immunol. 2016;196(1):97–105.
pubmed: 26621860
doi: 10.4049/jimmunol.1501175
Sgier C, Mullhaupt B, Gerlach T, Moradpour D, Negro F, Male PJ, Heim MH, Malinverni R, Cerny A, Dufour JF. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. J Viral Hepat. 2010;17(12):845–50.
pubmed: 20070503
doi: 10.1111/j.1365-2893.2009.01251.x
Boursier J, Decraecker M, Bourliere M, Bureau C, Ganne-Carrie N, de Ledinghen V. Quality criteria for the measurement of liver stiffness. Clin Res Hepatol Gastroenterol. 2022;46(1):101761.
pubmed: 34325013
doi: 10.1016/j.clinre.2021.101761
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.
pubmed: 12883497
doi: 10.1053/jhep.2003.50346
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski S, Torriani M, Dieterich FJ, Thomas DT. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.
pubmed: 16729309
doi: 10.1002/hep.21178
Mueller T, Dieplinger B. The Presage® ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn. 2013;13(1):13–30.
pubmed: 23256700
doi: 10.1586/erm.12.128
Presage ST2 test. [ https://www.lifebiomedical.com/presage-st2-test.html ].
Sun Z, Chang B, Gao M, Zhang J, Zou Z. IL-33-ST2 Axis in Liver Disease: progression and challenge. Mediators Inflamm. 2017;2017:5314213.
pubmed: 29180837
pmcid: 5664344
doi: 10.1155/2017/5314213
Ismail SA, El Saadany S, Ziada DH, Zakaria SS, Mayah WW, Elashry H, Arafa M, Elmashad N. Cytokeratin-18 in diagnosis of HCC in patients with liver cirrhosis. Asian Pac J cancer Prevention: APJCP. 2017;18(4):1105–11.
Murota M, Watanabe S, Fujita J, Ohtsuki Y, Wu F, Yoshida S, Kita Y, Funakoshi F, Masaki T, Kurokohchi K, et al. Aberrant cytokeratin expression and high susceptibility to apoptosis in autoimmune hepatitis. Hepatol Research: Official J Japan Soc Hepatol. 2003;25(3):271–80.
doi: 10.1016/S1386-6346(02)00277-2
Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012;19(4):278–82.
pubmed: 22404726
doi: 10.1111/j.1365-2893.2011.01546.x
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.
pubmed: 15685546
doi: 10.1053/j.gastro.2004.11.018
Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Sustained improvements in markers of Liver Disease Severity after Hepatitis C treatment. J Clin Exp Hepatol. 2020;10(2):114–23.
pubmed: 32189926
doi: 10.1016/j.jceh.2019.09.001
Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1–3.
pubmed: 19017551
doi: 10.1016/j.jhep.2008.10.014
Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50(1):36–41.
pubmed: 19012989
doi: 10.1016/j.jhep.2008.07.039
Patel K, Remlinger KS, Walker TG, Leitner P, Lucas JE, Gardner SD, McHutchison JG, Irving W, Guha IN. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2014;12(12):2113–2120e2111.
doi: 10.1016/j.cgh.2014.04.037
Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067.
pubmed: 32118201
pmcid: 7047178
doi: 10.1016/j.jhepr.2020.100067
Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Staging fibrosis in chronic viral Hepatitis. Viruses 2022, 14(4).
Bhattacharya D, Aronsohn A, Price J, Lo Re V, Hepatitis C. Guidance 2023 Update: AASLD-IDSA recommendations for Testing, Managing, and treating Hepatitis C virus infection. Clin Infect Dis 2023.
Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49(3):302–15.
pubmed: 26188920
doi: 10.1016/j.clinbiochem.2015.07.019
El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta-analysis. Arab J Gastroenterol. 2017;18(2):51–7.
pubmed: 28579340
doi: 10.1016/j.ajg.2017.05.005
Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33(1):138–48.
pubmed: 21083589
doi: 10.1111/j.1365-2036.2010.04500.x
Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut. 1980;21(1):63–71.
pubmed: 6988303
pmcid: 1419572
doi: 10.1136/gut.21.1.63
Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, et al. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS ONE. 2021;16(9):e0257166.
pubmed: 34506563
pmcid: 8432856
doi: 10.1371/journal.pone.0257166
Yamataka K, Chu PS, Koda Y, Taniki N, Morikawa R, Yoshida A, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, et al. Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: prognostic and metabolomic impacts. PLoS ONE. 2022;17(10):e0276925.
pubmed: 36301899
pmcid: 9612469
doi: 10.1371/journal.pone.0276925
Homsak E, Gruson D. Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta. 2020;507:75–87.
pubmed: 32305537
doi: 10.1016/j.cca.2020.04.011